Every 10-Q that Esperion Therapeutics, Inc. (ESPR) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow ESPR and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full ESPR filings page.
Esperion Therapeutics reported Q1 2026 revenue of $80.1 million, up from $65.0 million a year earlier, and a narrower net loss of $25.2 million versus $40.5 million. Product sales were $43.4 million and collaboration revenue $36.7 million, driven mainly by partners in Europe and Japan.
Cash and cash equivalents were $156.2 million, alongside substantial obligations including a $291.2 million royalty sale liability and $250 million of term and convertible debt. The company agreed to acquire Corstasis for $75 million plus up to $180 million in milestones, adding Enbumyst to its cardiovascular portfolio.
Separately, Esperion entered into a definitive merger agreement under which Essence Parent Inc. will acquire the company. Holders of common stock will receive $3.16 in cash per share plus one contingent value right tied to up to $100 million of potential milestone-based cash payments, subject to stockholder approval and customary conditions.
Esperion Therapeutics (ESPR) reported Q3 2025 results showing stronger top-line momentum but ongoing losses. Total revenue reached $87.3 million, up from $51.6 million a year ago, driven by product sales of $40.7 million (vs. $31.1 million) and collaboration revenue of $46.7 million (vs. $20.5 million). Operating loss narrowed to $10.0 million, but higher interest expense brought net loss to $31.3 million (vs. $29.5 million). Year‑to‑date, revenue was $234.7 million with a net loss of $84.5 million.
Cash and cash equivalents were $92.4 million as of September 30, 2025, with operating cash outflow of $58.3 million year‑to‑date. The balance sheet reflects a royalty sale liability of $294.2 million (interest expense $14.6 million in Q3) and long‑term debt of $151.7 million under a December 2024 credit agreement. Accounts receivable grew to $119.0 million and inventories to $108.5 million, supporting higher sales. The company settled several generic challenges in 2025 and continues defending remaining ANDA cases; certain asserted patents extend into 2040. Shares outstanding were 239,063,437 as of October 31, 2025.
Esperion Therapeutics reported continued U.S. commercial momentum for its oral, non‑statin LDL‑C medicines as product sales rose to $40.3 million in Q2 2025 and $75.2 million for the six months ended June 30, 2025, up from $28.3 million and $53.1 million in the comparable 2024 periods, indicating stronger prescriptions and channel activity.
Collaboration revenue was approximately $42.1 million in Q2 2025 and $72.2 million year‑to‑date, down from $158.5 million for the prior six‑month period largely because prior‑year results included larger milestone recognition. Cash and cash equivalents declined to $86.1 million at June 30, 2025 from $144.8 million at December 31, 2024. Total assets were $347.1 million and total liabilities increased to $780.6 million, resulting in a stockholders' deficit of $(433.5) million.
The company recognized notable finance and capital transactions: proceeds from a $304.7 million sale of future DSE royalties are recorded as a royalty sale liability of approximately $295.9 million (net of issuance costs), and it maintains long‑term debt from a $150.0 million term loan with a carrying amount of $146.5 million. Interest expense increased year‑over‑year and contributed to a consolidated net loss of $53.18 million for the six months ended June 30, 2025. Esperion settled patent disputes with three ANDA filers who agreed not to market a generic version of NEXLETOL in the U.S. before April 19, 2040, while litigation against remaining ANDA filers continues.